Key result
Amlodipine plus folic acid lowers BP and homocysteine while improving endothelial function versus amlodipine alone.
Why the study?
Hypertension combined with hyperhomocysteinemia increases cardiovascular risk, and the effects of amlodipine-folic acid combination on these conditions require investigation.
Hypothesis-generating for amlodipine-folic acid in hypertension; leaves open any clinical role pending human trials.
Objectives To investigate the actions of amlodipine-folic acid (amlodipine-FA) preparation on hypertension and cardiovascular in renal hypertensive rats with hyperhomocysteinemia (HHcy), so as to provide experimental basis for clinical research of amlodipine folic acid tablets.Methods Rats model of renal hypertension with HHcy were established. The rats were randomly divided into groups of model, amlodipine, folic acid (FA) and amlodipine-FA of various dosages. Normal rats were used as normal control group. Blood pressure, Hcy as well as plasma NO, ET-1 and hemodynamics were assayed. Histological alterations of heart and abdominal aorta were also examined.Results Compared with the normal group, blood pressure, plasma Hcy, and NO of the rats in model group were significantly increased, while the plasma ET-1 was decreased. Compared with the normal group, the animals in the model group had reduced cardiac function, thickened wall of the aorta and narrowed lumen. In FA group and amlodipine group, the rat plasma NO was increased while ET-1 was decreased, the protective effect of amlodipine-FA group on endothelial cells was further enhanced. In amlodipine group, the rat hemodynamics (LVSP, LVEDP and ±dp/dtmax, et al.) and vascular damage were significantly reduced, while in amlodipine-FA group, the heart function were further improved, and myocardial and vascular hypertrophy were significantly reduced.Conclusions As compared to amlodipine alone, amlodipine -FA can lower both blood pressure and plasma Hcy, significantly enhancing vascular endothelial function to protect the heart and blood vessel in renal hypertensive rats with HHcy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied Renal hypertension with hyperhomocysteinemia (n=98). Amlodipine-folic acid vs. Amlodipine alone, folic acid alone, and untreated model control was evaluated on Blood pressure and plasma homocysteine levels. Compared to amlodipine alone, the amlodipine-folic acid combination lowered both blood pressure and plasma homocysteine, significantly enhancing vascular endothelial function in hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: